Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Seagen Inc. SGEN
$198.92
-$0.58 (-0.29%)
На 18:00, 12 мая 2023
-13.78%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
37476424480.00000000
-
week52high
207.17
-
week52low
116.08
-
Revenue
1962412000
-
P/E TTM
-171
-
Beta
0.53391000
-
EPS
-3.48000000
-
Last Dividend
0.00000000
-
Next Earnings Date
26 июл 2023 г. в 10:59
Описание компании
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| RBC Capital | Outperform | Sector Perform | 16 авг 2022 г. |
| SVB Leerink | Outperform | Outperform | 15 авг 2022 г. |
| Morgan Stanley | Overweight | Overweight | 29 июл 2022 г. |
| Needham | Buy | Buy | 27 июл 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 27 июл 2022 г. |
| SVB Leerink | Outperform | Outperform | 13 сент 2022 г. |
| Morgan Stanley | Overweight | Overweight | 13 окт 2022 г. |
| BMO Capital | Outperform | Market Perform | 11 окт 2022 г. |
| RBC Capital | Outperform | Outperform | 28 окт 2022 г. |
| Raymond James | Outperform | Outperform | 28 окт 2022 г. |
| Morgan Stanley | Overweight | Overweight | 28 окт 2022 г. |
| Barclays | Equal-Weight | Equal-Weight | 28 окт 2022 г. |
| JP Morgan | Overweight | Overweight | 24 окт 2022 г. |
| JMP Securities | Market Outperform | Market Outperform | 02 ноя 2022 г. |
| Truist Securities | Hold | 21 ноя 2022 г. | |
| Berenberg | Buy | Buy | 25 янв 2023 г. |
| Morgan Stanley | Overweight | Overweight | 24 янв 2023 г. |
| SVB Leerink | Outperform | Outperform | 20 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| DANSEY ROGER D | D | 96853 | 783 | 02 февр 2023 г. |
| LIU JEAN I | D | 22446 | 5000 | 24 янв 2023 г. |
| LIU JEAN I | D | 85113 | 5000 | 24 янв 2023 г. |
| LIU JEAN I | A | 90113 | 5000 | 24 янв 2023 г. |
| DANSEY ROGER D | D | 48083 | 10000 | 24 янв 2023 г. |
| DANSEY ROGER D | D | 97539 | 10000 | 24 янв 2023 г. |
| DANSEY ROGER D | A | 107539 | 10000 | 24 янв 2023 г. |
| LIU JEAN I | D | 85113 | 578 | 17 янв 2023 г. |
| DANSEY ROGER D | A | 105039 | 7500 | 05 янв 2023 г. |
| LIU JEAN I | D | 27446 | 4525 | 05 янв 2023 г. |
Новостная лента
Seattle Genetics (SGEN) Reports Q1 Loss, Lags Revenue Estimates
Zacks Investment Research
27 апр 2023 г. в 10:38
Seattle Genetics (SGEN) came out with a quarterly loss of $0.93 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to loss of $0.74 per share a year ago.
Consider This Undervalued Pharma Giant Before Its Blockbuster Deal Closes
The Motley Fool
17 апр 2023 г. в 09:13
Pfizer's cash deal for Seagen benefits shareholders. Seagen's pipeline of antibody-drug conjugates (ADCs) looks promising.
Seagen to Report First Quarter 2023 Financial Results on April 27, 2023
Business Wire
07 апр 2023 г. в 08:00
BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced that it will report its first quarter 2023 financial results on Thursday, April 27, 2023. Given the recently announced agreement to be acquired by Pfizer Inc., Seagen will not be hosting a conference call. About Seagen Seagen is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people's lives.
Seagen's (SGEN) Padcev & Keytruda Combo Gets FDA Accelerated Nod
Zacks Investment Research
04 апр 2023 г. в 12:10
The FDA grants accelerated approval to Seagen (SGEN) and partner, Astellas' combination therapy of Padcev with Merck's Keytruda for the treatment of first and second-line metastatic urothelial cancer.
Seagen founder Clay Siegall is back in biotech as CEO of Purdue University spinout
GeekWire
22 мар 2023 г. в 19:16
Clay Siegall, the Seagen founder who resigned last year following an arrest and allegations of domestic violence, is jumping back into the biotech world as CEO and president of Morphimmune.